Access the full text.
Sign up today, get DeepDyve free for 14 days.
Po-Lin Lin, Chun-Che Huang, Yih-Jer Wu, M. Su, Wei-Ru Chiou, Lawrence Liu, Feng-Ching Liao, Edward Lai, Chun-Yen Chen, J. Kuo, Ying-Hsiang Lee (2019)
Relations between baseline burden, maximum duration, and relative reduction of atrial fibrillation: Insights from continuous monitoring in rhythm controlJournal of Cardiovascular Electrophysiology, 30
H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H. Diener, W. Hacke, J. Oldgren, P. Sinnaeve, A. Camm, Paulus Kirchhof, Paulus Kirchhof (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 17 10
Y. Chan, L. See, H. Tu, Yung-Hsin Yeh, Shang-Hung Chang, Lung‐Sheng Wu, Hsin-Fu Lee, Chun-Li Wang, C. Kuo, C. Kuo (2018)
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial FibrillationJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 7
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, Bogdan Popescu, U. Schotten, B. putte, P. Vardas (2017)
2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS.Revista espanola de cardiologia, 70 1
P. Abrams, C. Emerson (2009)
Rivaroxaban: A Novel, Oral, Direct Factor Xa InhibitorPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 29
Hsin-Fu Lee, Y. Chan, H. Tu, C. Kuo, Yung-Hsin Yeh, Shang-Hung Chang, Lung‐Sheng Wu, L. See (2018)
The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.International journal of cardiology, 261
P. Santangeli, L. Biase, L. Biase, G. Pelargonio, J. Burkhardt, A. Natale (2011)
The pharmaceutical pipeline for atrial fibrillationAnnals of Medicine, 43
(2016)
ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhyth Cardiac Electrophysiology
L. Friberg (2018)
Safety of apixaban in combination with dronedarone in patients with atrial fibrillation.International journal of cardiology, 264
E. Heist, M. Mansour, J. Ruskin (2011)
Rate Control in Atrial Fibrillation: Targets, Methods, Resynchronization ConsiderationsCirculation, 124
I. Celikyurt, C. Meier, M. Kühne, B. Schaer (2017)
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic DrugsDrug Safety, 40
S. Schulman, U. Angerås, D. Bergqvist, B. Eriksson, M. Lassen, W. Fisher (2010)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 8
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, B. Popescu, U. Schotten, B. putte, P. Vardas, S. Agewall, J. Camm, G. Esquivias, W. Budts, S. Carerj, F. Casselman, A. Coca, R. Caterina, S. Deftereos, D. Dobrev, J. Ferro, G. Filippatos, D. Fitzsimons, B. Gorenek, M. Guenoun, S. Hohnloser, P. Kolh, G. Lip, A. Manolis, J. McMurray, P. Ponikowski, R. Rosenhek, F. Ruschitzka, I. Savelieva, Sanjay Sharma, P. Suwalski, J. Tamargo, C. Taylor, I. Gelder, A. Voors, S. Windecker, J. Zamorano, K. Zeppenfeld (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 18 11
C. Chiang, T. Wu, K. Ueng, T. Chao, Kuan-Cheng Chang, Chun-Chieh Wang, Yenn-Jiang Lin, W. Yin, J. Kuo, Wei-Shiang Lin, Chia-Ti Tsai, Yen‐Bin Liu, Kun-Tai Lee, Li‐Jen Lin, Lian‐Yu Lin, Kang-Ling Wang, Yi‐Jen Chen, Mien-Cheng Chen, Chen-Chuan Cheng, M. Wen, Wen-Jone Chen, Jyh‐Hong Chen, W. Lai, C. Chiou, Jiunn-lee Lin, S. Yeh, Shih‐Ann Chen (2016)
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation.Journal of the Formosan Medical Association = Taiwan yi zhi, 115 11
M. Patel, K. Mahaffey, Jyotsna Garg, Guohua Pan, D. Singer, W. Hacke, G. Breithardt, J. Halperin, G. Hankey, J. Piccini, R. Becker, C. Nessel, J. Paolini, S. Berkowitz, K. Fox, R. Califf (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 10
(2018)
European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
T. Fleming, S. Emerson (2011)
Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.The New England journal of medicine, 365 17
E. Szczerba (2012)
[Summary of the article: Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 1557-1559].Kardiologia polska, 70 1
M. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, S. Sandmann (2011)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of RivaroxabanJournal of Pharmacology and Experimental Therapeutics, 338
S. Kaatz, D. Ahmad, A. Spyropoulos, A. Spyropoulos, S. Schulman (2015)
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 13
Shang-Hung Chang, I. Chou, Yung-Hsin Yeh, Meng‐Jiun Chiou, M. Wen, C. Kuo, L. See, Chang-Fu Kuo (2017)
Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial FibrillationJAMA, 318
D. Wyse, A. Waldo, J. Dimarco, M. Domanski, Y. Rosenberg, Eleanor Schron, J. Kellen, H. Greene, M. Mickel, J. Dalquist, S. Corley (2002)
A comparison of rate control and rhythm control in patients with atrial fibrillation.The New England journal of medicine, 347 23
S. Schulman, C. Kearon (2005)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 3
T. Ikeda, S. Ogawa, T. Kitazono, J. Nakagawara, K. Minematsu, S. Miyamoto, Y. Murakawa, M. Takeichi, Y. Ohashi, Yutaka Okayama, T. Sunaya, S. Yamanaka (2019)
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).Journal of cardiology, 74 1
C. Escobar, Martín Arceluz, Rosa Oca, R. Mori, J. López-Sendón, J. Merino (2017)
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.Revista espanola de cardiologia, 70 2
S. Hohnloser, H. Crijns, Martin Eickels, C. Gaudin, R. Page, C. Torp-Pedersen, S. Connolly (2009)
Effect of dronedarone on cardiovascular events in atrial fibrillation.The New England journal of medicine, 360 7
Carlos Escobar, Martín Arceluz, Rosana Oca, Ricardo Mori, J. López-Sendón, J. Merino (2017)
Administración simultánea de rivaroxabán y dronedarona en pacientes con fibrilación auricular no valvularRevista Espanola De Cardiologia, 70
J. Steffel, P. Verhamme, T. Potpara, P. Albaladéjo, M. Antz, L. Desteghe, K. Haeusler, J. Oldgren, H. Reinecke, V. Roldán-Schilling, N. Rowell, P. Sinnaeve, R. Collins, A. Camm, H. Heidbüchel, G. Lip, J. Weitz, L. Fauchier, D. Lane, G. Boriani, A. Goette, R. Keegan, R. Macfadyen, C. Chiang, B. Joung, W. Shimizu (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.European heart journal, 39 16
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds (2011)
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 13 3
H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, P. Sinnaeve, A. Camm, P. Kirchhof, P. Kirchhof (2013)
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 15 5
(2016)
Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation
P. Kirchhof, A. Camm, A. Goette, A. Brandes, L. Eckardt, A. Elvan, T. Fetsch, I. Gelder, D. Haase, L. Haegeli, F. Hamann, H. Heidbüchel, G. Hindricks, J. Kautzner, K. Kuck, L. Mont, G. Ng, J. Rekosz, N. Schoen, U. Schotten, A. Suling, J. Taggeselle, S. Themistoclakis, E. Vettorazzi, P. Vardas, K. Wegscheider, S. Willems, H. Crijns, G. Breithardt (2020)
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.The New England journal of medicine
T. Trujillo, P. Nolan (2000)
Antiarrhythmic AgentsDrug Safety, 23
IntroductionRivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm. Current guidelines contraindicate concomitant use of rivaroxaban with the popular AAD dronedarone, despite little data demonstrating interactions with AADs. This study investigates the outcomes of concomitant rivaroxaban and AAD drug use in a real-world cohort.MethodsThis retrospective study included 1777 non-permanent AF patients taking rivaroxaban for ≥ 1 month between 2011 and 2016 from a multicenter cohort in Taiwan, and compared concomitant AAD use against clinical outcome endpoints for safety, effectiveness, and major adverse cardiac events (MACE). Multivariate Cox proportional hazard analyses were used to evaluate the association between concomitant AAD use and outcomes.ResultsPatients were divided into rivaroxaban alone (n = 1205) and with concomitant amiodarone (n = 177), dronedarone (n = 231), or propafenone (n = 164) groups. The proportion of patients using rivaroxaban 10 mg was highest in the concomitant dronedarone group: rivaroxaban alone, 53.6%; with amiodarone, 57.6%; with dronedarone, 77.1%; and with propafenone, 46.3% (p < 0.001). The cumulative incidences of safety (p = 0.892), effectiveness (p = 0.336), and MACE (p = 0.674) were similar between the four groups; however, there were significantly fewer new systemic thromboembolisms in the dronedarone group: rivaroxaban alone, 2.5%; with amiodarone, 0.6%; with dronedarone, 0%; and with propafenone, 1.2% (p = 0.029). The all-cause death rate was also lowest in the dronedarone group: rivaroxaban alone, 9.0%; with amiodarone, 9.6%; with dronedarone, 3.0%; and with propafenone: 6.1% (p = 0.013). After covariate adjustment, there were no differences in the safety, effectiveness, and MACE endpoints between patients receiving or not receiving AADs.ConclusionConcomitant use of rivaroxaban with AADs appears to be well tolerated, warranting further investigation into the apparent benefits of a reduced dose of rivaroxaban combined with dronedarone.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 28, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.